Trial Profile

A Phase 1/2 Study of BMS-986408 Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS-986408 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Rabeprazole (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Malignant melanoma; Neuroblastoma; Solid tumours
Focus Adverse reactions
Sponsors Bristol-Myers Squibb

Most Recent Events

12 Mar 2024 Planned number of patients changed from 113 to 407.
12 Mar 2024 Planned End Date changed from 26 Mar 2027 to 14 Oct 2025.
12 Mar 2024 Planned primary completion date changed from 26 Mar 2027 to 14 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com